---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-208966"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T23:05:03.554916+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sarepta Q1 GAAP EPS $2.88 vs loss of $4.60; siRNA pipeline shows early positive data

## Summary
- Net product revenue $330.5M (ELEVIDYS $102.0M, PMO $228.6M); total rev $730.8M (-2% YoY).
- GAAP net income $331.0M vs loss of $447.5M; non-GAAP net income $385.4M.
- siRNA candidates SRP-1001 (FSHD1) and SRP-1003 (DM1) show dose-dependent exposure and biomarker effects in Phase 1/2.
- sNDA submitted to convert AMONDYS 45 and VYONDYS 53 to traditional approval; FY guidance reaffirmed $1.2-1.4B revenue.
- ENDEAVOR Cohort 8 dosing underway for non-ambulatory DMD with sirolimus pretreatment; $40M milestone from Japan.

## SEC filing metadata
- accession: 0001193125-26-208966
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312526208966/0001193125-26-208966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312526208966/srpt-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-208966
- JSON: https://secwatch.observer/filing/0001193125-26-208966.json
- Plain text: https://secwatch.observer/filing/0001193125-26-208966.txt

## Source-grounded claims
- claim_id: 35b9c15265d0cc28d00e96ec29a69a84909170e2
  claim: Sarepta Therapeutics, Inc. reported first quarter 2026 results: revenue $330.5 million, net income $331.0 million, EPS $2.88. Guidance reaffirmed.
  evidence_excerpt: Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments – Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues – Achieved GAAP and non-GAAP operating income of $358.4 million and $397.7 million for the first quarter 2026, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312526208966/0001193125-26-208966-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.